AOD9604 Lipolytic Peptide

Modified fragment of human growth hormone (hGH 177-191) investigated for lipolysis signaling without affecting blood glucose levels.

Transparent Pricing₦150,000 / protocol

START PRE-CONSULTATION ASSESSMENTarrow_forward CHAT ON WHATSAPP ABOUT PROTOCOL

infoResearch & Clinical Context

Targeted fat mobilization research protocol.

Mechanism & Biological Overview

AOD9604 is a modified peptide fragment corresponding to the C-terminal region of human growth hormone (hGH 177-191). It selectively stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis without impacting IGF-1 levels, glycemic control, or tissue growth.

Key Biological Highlights & Benefits

checkSelective lipolytic signaling (fat mobilization)
checkDoes not alter blood glucose or insulin sensitivity
checkFree from growth hormone receptor growth-promoting side effects
checkTargeted metabolic support

menu_book

Scientific Literature Abstract

"AOD9604 retains the lipolytic activity of intact growth hormone while lacking anabolic properties. Studies demonstrate stimulation of triglyceride breakdown in adipocytes via beta-3 adrenergic signaling independent of growth hormone receptors."

hubTarget Receptor Pathways

Beta-3 Adrenergic Lipolytic Cascades

Inhibition of Acetyl-CoA Carboxylase (Lipogenesis)

hGH 177-191 C-Terminal Domain Binding

Frequently Asked Questions

Does AOD9604 affect growth hormone or IGF-1 levels?

No. Studies demonstrate that AOD9604 acts specifically on lipolytic pathways without altering serum IGF-1 or blood glucose.

Explore Related Scientific Interventions

Metabolic Health₦145,000 / month

Semaglutide Protocol

A GLP-1 receptor agonist studied for appetite modulation and glycemic signaling pathways in metabolic health.

View Full Details arrow_forward

Weight Management₦210,000 / month

Tirzepatide Dual Agonist

Dual GIP and GLP-1 receptor agonist targeting complementary metabolic pathways for body composition and appetite research.

View Full Details arrow_forward

Weight Management₦280,000 / month

Retatrutide Triple Agonist

Triple receptor agonist (GIP, GLP-1, and Glucagon) studied for its potential effects on metabolic rate and lipid mobilization pathways.

View Full Details arrow_forward

gavel

Clinical & Legal Disclaimer

Medical Disclaimer: Information provided on this website is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Product availability, indications, regulatory status, and suitability may vary. Any medical treatment should be considered with an appropriately qualified healthcare professional.

NOVAMET does not guarantee specific weight-loss, metabolic, or treatment outcomes.